Drugs / Edasalonexent
Edasalonexent
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04543370 | Aug → Sep 2020 | — | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01670773 | Aug → Oct 2012 | — | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01511900 | Dec 2011 → Apr 2012 | type 2 diabetes mellitus | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01440166 | Sep 2011 → Jan 2012 | — | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02439216 | Apr 2016 → Jan 2017 | Duchenne muscular dystrophy | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03917719 | Mar 2019 → Oct 2020 | Duchenne muscular dystrophy | Catabasis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03703882 | Oct 2018 → Sep 2020 | Duchenne muscular dystrophy | Catabasis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Edasalonexent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04543370 ↗ |
| Known as | CAT-1004 | “Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004” NCT01511900 ↗5“Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.” NCT01440166 ↗ “Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.” NCT01440166 ↗ “CAT-1004” NCT03703882 ↗ |
| Known as | Edasalonexento | ChEMBL registry synonym — accepted as the source's own label CHEMBL3786673 ↗ |
| Action | Inhibit | “targeted to inhibit activated NF-κB” NCT02439216 ↗ |
| Modality | Small molecule | “Edasalonexent is an orally administered small molecule” NCT02439216 ↗ |
| Route | Oral | “Single dose oral administration” NCT01440166 ↗ |